Your browser doesn't support javascript.
loading
Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study.
Miller, Natalie J; Khaki, Ali Raza; Diamantopoulos, Leonidas N; Bilen, Mehmet A; Santos, Victor; Agarwal, Neeraj; Morales-Barrera, Rafael; Devitt, Michael; Nelson, Ariel; Hoimes, Christopher J; Shreck, Evan; Assi, Hussein; Gartrell, Benjamin A; Sankin, Alex; Rodriguez-Vida, Alejo; Lythgoe, Mark; Pinato, David J; Drakaki, Alexandra; Joshi, Monika; Isaacsson Velho, Pedro; Hahn, Noah; Liu, Sandy; Alonso Buznego, Lucia; Duran, Ignacio; Moses, Marcus; Jain, Jayanshu; Murgic, Jure; Barata, Pedro; Tripathi, Abhishek; Zakharia, Yousef; Galsky, Matthew D; Sonpavde, Guru; Yu, Evan Y; Lyman, Gary H; Grivas, Petros.
Afiliação
  • Miller NJ; Division of Oncology, Department of Medicine, University of Washington, Seattle, Washington.
  • Khaki AR; Division of Oncology, Department of Medicine, University of Washington, Seattle, Washington.
  • Diamantopoulos LN; Division of Oncology, Department of Medicine, University of Washington, Seattle, Washington.
  • Bilen MA; Winship Cancer Institute of Emory University, Atlanta, Georgia.
  • Santos V; Department of Medicine, University of Utah, Salt Lake City, Utah.
  • Agarwal N; Department of Medicine, University of Utah, Salt Lake City, Utah.
  • Morales-Barrera R; Vall d´Hebron Institute of Oncology, Vall d´Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Devitt M; Division of Hematology/Oncology, Department of Medicine, University of Virginia School of Medicine, Charlottesville, Virginia.
  • Nelson A; Division of Hematology/Oncology, Department of Medicine, Case Comprehensive Cancer Center, Cleveland, Ohio.
  • Hoimes CJ; Division of Hematology/Oncology, Department of Medicine, Case Comprehensive Cancer Center, Cleveland, Ohio.
  • Shreck E; Departments of Medical Oncology and Urology, Montefiore Medical Center, Bronx, New York.
  • Assi H; Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
  • Gartrell BA; Departments of Medical Oncology and Urology, Montefiore Medical Center, Bronx, New York.
  • Sankin A; Departments of Medical Oncology and Urology, Montefiore Medical Center, Bronx, New York.
  • Rodriguez-Vida A; Medical Oncology Department, Hospital del Mar Research Institute, Barcelona, Spain.
  • Lythgoe M; Division of Medicine, Imperial College London, London, United Kingdom.
  • Pinato DJ; Division of Medicine, Imperial College London, London, United Kingdom.
  • Drakaki A; Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, Los Angeles, California.
  • Joshi M; Division of Hematology/Oncology, Department of Medicine, Penn State Cancer Institute, Hershey, Pennsylvania.
  • Isaacsson Velho P; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland.
  • Hahn N; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland.
  • Liu S; Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, Los Angeles, California.
  • Alonso Buznego L; Hospital Universitario Marques de Valdecilla, IDIVAL, Santander, Spain.
  • Duran I; Hospital Universitario Marques de Valdecilla, IDIVAL, Santander, Spain.
  • Moses M; Department of Medicine and Oncology, Tulane University, New Orleans, Louisiana.
  • Jain J; Department of Medicine, University of Iowa, Iowa City,Iowa.
  • Murgic J; Department of Oncology and Nuclear Medicine, University Hospital Center Sisters of Charity Zagreb School of Medicine, Zagreb, Croatia.
  • Barata P; Department of Medicine and Oncology, Tulane University, New Orleans, Louisiana.
  • Tripathi A; Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
  • Zakharia Y; Division of Oncology, Department of Medicine, University of Iowa, Iowa City, Iowa.
  • Galsky MD; Division of Oncology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Sonpavde G; Genitourinary Oncology Program, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Yu EY; Division of Oncology, Department of Medicine, University of Washington, Seattle, Washington.
  • Lyman GH; Division of Oncology, Department of Medicine, University of Washington, Seattle, Washington.
  • Grivas P; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
J Urol ; 204(1): 63-70, 2020 07.
Article em En | MEDLINE | ID: mdl-31971495
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma / Neoplasias Urológicas / Anticorpos Monoclonais Humanizados / Receptor de Morte Celular Programada 1 / Antineoplásicos Imunológicos Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male Idioma: En Revista: J Urol Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma / Neoplasias Urológicas / Anticorpos Monoclonais Humanizados / Receptor de Morte Celular Programada 1 / Antineoplásicos Imunológicos Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male Idioma: En Revista: J Urol Ano de publicação: 2020 Tipo de documento: Article